Mendus shows early comparability data for its universal cancer vaccine

Mendus has announced that the immune response triggered by vididencel was comparable for patients with acute myeloid leukaemia (AML) and ovarian cancer.

The immune response validates the proposed mechanism of action for the vaccine and solidifies vididencel’s applicability across different cancers, as per the company. Two data sets will be presented at the International Cancer Immunotherapy Conference (CICON23) in Milan, Italy, on 22 September.